REPORT OF THE BOARD OF THE IRISH
Irish Stock Exchange
28 Anglesea Street
20th March 2017
The board of the Irish Stock Exchange approves the admission of the undermentioned securities to listing on the Official List and trading on the Global Exchange Market of the ISE.
THERAVANCE BIOPHARMA, INC.
USD 230,000,000 principal amount of its 3.25% Convertible Senior Notes due 2023 US88339KAA07
This announcement has been issued through the Companies Announcement Service of
the Irish Stock Exchange.